Medicinova (MNOV) Cash & Equivalents (2010 - 2025)

Medicinova (MNOV) has 16 years of Cash & Equivalents data on file, last reported at $30.8 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 23.67% year-over-year to $30.8 million in Q4 2025; TTM through Dec 2025 was $30.8 million, a 23.67% decrease from a year earlier, with the FY2025 full-year figure at $30.8 million, down 23.67% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $30.8 million, down from $32.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MNOV reached as high as $77.8 million in Q2 2021 and fell as low as $18.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $51.2 million across 5 years, with a median of $51.3 million in 2023.
• Across the five-year window, Cash & Equivalents plunged 74.09% in 2022 and soared 175.59% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $71.4 million in 2021, then plunged by 74.09% to $18.5 million in 2022, then surged by 175.59% to $51.0 million in 2023, then slipped by 20.86% to $40.4 million in 2024, then dropped by 23.67% to $30.8 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $30.8 million in Q4 2025, $32.6 million in Q3 2025, and $34.3 million in Q2 2025.